- Home
- KZIA vs APRE Comparison
KZIA vs APRE Comparison
Compare KZIA & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- APRE
- Stock Information
- Founded
- KZIA 1994
- APRE 2006
- Country
- KZIA Australia
- APRE United States
- Employees
- KZIA N/A
- APRE N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KZIA Health Care
- APRE Health Care
- Exchange
- KZIA Nasdaq
- APRE Nasdaq
- Market Cap
- KZIA 9.0M
- APRE 9.4M
- IPO Year
- KZIA 1999
- APRE 2019
- Fundamental
- Price
- KZIA $7.94
- APRE $1.50
- Analyst Decision
- KZIA Strong Buy
- APRE Strong Buy
- Analyst Count
- KZIA 2
- APRE 1
- Target Price
- KZIA $14.00
- APRE $20.00
- AVG Volume (30 Days)
- KZIA 137.3K
- APRE 33.7K
- Earning Date
- KZIA 11-14-2025
- APRE 11-06-2025
- Dividend Yield
- KZIA N/A
- APRE N/A
- EPS Growth
- KZIA N/A
- APRE N/A
- EPS
- KZIA N/A
- APRE N/A
- Revenue
- KZIA $1,549,158.00
- APRE $841,012.00
- Revenue This Year
- KZIA N/A
- APRE N/A
- Revenue Next Year
- KZIA $49.25
- APRE N/A
- P/E Ratio
- KZIA N/A
- APRE N/A
- Revenue Growth
- KZIA 248983.08
- APRE N/A
- 52 Week Low
- KZIA $2.86
- APRE $1.41
- 52 Week High
- KZIA $39.05
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- KZIA 48.43
- APRE 41.55
- Support Level
- KZIA $7.60
- APRE $1.44
- Resistance Level
- KZIA $8.28
- APRE $1.66
- Average True Range (ATR)
- KZIA 0.51
- APRE 0.08
- MACD
- KZIA 0.03
- APRE -0.00
- Stochastic Oscillator
- KZIA 30.88
- APRE 26.67
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.